4-AcO-DMT is a substance of the tryptamine class. It is a structural analog of psilocybin, the active ingredient in psilocybin mushrooms. Like psilocybin, it is thought to produce its effects primarily by binding to serotonin receptors in the brain.
https://t.co/TCbZ38ZzhV
UK-based Beckley Psytech has received Clinical Trial Authorisation from UK authorities, allowing it to explore the effects of psilocybin in the treatment of short-lasting unilateral neuralgiform headache attacks (SUNHA).
https://t.co/FIRO0p5YJP
The progression of clinical trials in recent years using psychedelic medicines: psilocybin, LSD and MDMA, to treat mental-health disorders, such as PTSD, MDD, SUD and anxiety, moves forward. @nresearchnews https://t.co/fIq7mZudyz
Leading scientists continue to remove roadblocks by developing methods for synthesizing psychedelic compounds for further research.
https://t.co/dmNRBjwJAB
How can psychedelics have therapeutic potential—for example, in the treatment of depression—if they reproduce symptoms similar to those of serious pathologies?
https://t.co/PuRd0moPZH
Ibogaine vs. Iboga Alkaloids for Treating Addiction:
Novel variants, may offer therapeutic benefits without severe side effects (re: heart). Research on this compound is important to creating a more universally safe treatment. By Alexandria H. Jaeger, MSC https://t.co/ZWhH7R8Img
Psilocybe plutonia is a small psilocybin mushroom of the family Strophariaceae, believed to contain psilocybin and psilocin. It was first documented from Cuba. An older synonym is Agaricus plutonia. Photo: unknown
Syzygium aromaticum L. (Myrtaceae): Traditional Uses, Bioactive Chemical Constituents, Pharmacological and Toxicological Activities https://t.co/eh74Kp7uFs